Can-Fite Presents Final Positive Data from Phase IIa Pancreatic Cancer Study of Namodenoson at ESMO 2026
Can-Fite presented final Phase IIa data for namodenoson in advanced pancreatic ductal adenocarcinoma at the ESMO 2026 Congress, with the primary safety endpoint achieved and only mild-to-moderate treatment-related adverse events across 20 enrolled patients. Exploratory analyses showed median overall survival of 6.28 months in third-line patients surviving beyond two months, and one second-line patient achieved 16.39 months progression-free survival and over 20.7 months overall survival.
Key figures
- Drug Name
- Namodenoson
- Phase Of Trial
- Phase IIa
- Dose
- 25 mg twice daily
- Data cutoff
- September 23, 2026
- Patients enrolled
- 20
- Third line median pfs months
- 2.27
- Second line patient os months
- 20.7
- Second line patient pfs months
- 16.39
- Third line median overall survival months
- 6.28
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.